Revenues hurt by patent expirations and currency fluctuations.
Pharmaceuticals revenues -4.7% to $8.45B, dragged down by generic competition for Merck's Singulair treatment for allergy and asthma; consumer care -4.4%; animal-health -3.2%.
Sales of Remicade, Simponi and Isentress, as well as of Diabetes and Vaccines Franchises, grew.
Affirms FY guidance for adjusted EPS of $3.35-3.53 vs consensus of $3.45.
Shares +1.45% premarket. (PR)